Polyclonal Antibody to Fatty Acid Binding Protein 4, Adipocyte (FABP4)
| Code | Size | Price |
|---|
| PAB693Ra01-20ul | 20ul | £89.00 |
Quantity:
| PAB693Ra01-100ul | 100ul | £166.00 |
Quantity:
| PAB693Ra01-200ul | 200ul | £224.00 |
Quantity:
| PAB693Ra01-1ml | 1ml | £515.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Rat
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
A-FABP; AFABP; AP2; Fatty Acid Binding Protein 4, Adipocyte; Adipocyte Protein 2; Adipocyte-type fatty acid-binding protein
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Fatty Acid Binding Protein 4
Reactivity:
Hu;Mu;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;1:150-600
Immunohistochemistry: 5-20ug/mL;1:15-60
Immunocytochemistry: 5-20ug/mL;1:15-60
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;1:15-60
Immunocytochemistry: 5-20ug/mL;1:15-60
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Fatty Acid Binding Protein 4, Adipocyte (FABP4) | RPB693Ra01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||